Hydroxychloroquine Therapy in Systemic Lupus Erythematosus

Clinical Guidelines and Recommendations

The European League Against Rheumatism recommends hydroxychloroquine for all patients with Systemic Lupus Erythematosus due to its beneficial effects, including reduction of disease flares, prevention of organ damage, and improved survival 1
Hydroxychloroquine prevents disease flares and reduces thrombotic events, allowing for glucocorticoid dose reduction, with a significant reduction in mortality risk 1
The daily dose of hydroxychloroquine should not exceed 5 mg/kg real body weight to minimize toxicity risk, as recommended by the European League Against Rheumatism 1
Annual ophthalmologic examination should begin after 5 years of therapy, or after 1 year if additional risk factors are present, to monitor for retinal toxicity 3
Retinal toxicity is the most common serious adverse effect of hydroxychloroquine, occurring in 0.5% after 6 years and potentially exceeding 20% after 20 years of use, according to the American College of Rheumatology 2

If hallucinations develop on hydroxychloroquine, the medication should be immediately discontinued and neurology/psychiatric consultation should be obtained to exclude other causes, as recommended by the American College of Rheumatology 3
Alternative antimalarials, such as quinacrine, may be considered for cutaneous manifestations if hydroxychloroquine cannot be reintroduced, according to the European League Against Rheumatism 1
Intensify immunosuppressive therapy to maintain disease control without hydroxychloroquine, using agents like azathioprine or methotrexate, as recommended by the European League Against Rheumatism 1